Limits...
Systemic Chemotherapy for Progression of Brain Metastases in Extensive-Stage Small Cell Lung Cancer.

Abdel Karim N, Bhatt A, Chiec L, Curry R - Case Rep Oncol Med (2015)

Bottom Line: Approximately 10%-14% of small cell lung cancer patients exhibit brain metastases at the time of diagnosis, which increases to 50%-80% as the disease progresses.Mean survival with brain metastases is reported to be less than six months, thus calling for improved regimens.Here we present a case series of patients treated with irinotecan for progressive brain metastases in small cell lung cancer, which serves as a reminder of the role of systemic chemotherapy in this setting.

View Article: PubMed Central - PubMed

Affiliation: The Vontz Center for Molecular Studies, Cincinnati, OH 45267, USA.

ABSTRACT
Lung cancer is the most common cause of cancer related mortality in men and women. Approximately 15% of lung cancers are small cell type. Chemotherapy and radiation are the mainstay treatments. Currently, the standard chemotherapy regimen includes platinum/etoposide. For extensive small cell lung cancer, irinotecan and cisplatin have also been used. Patients with relapsed small cell lung cancer have a very poor prognosis, and the morbidity increases with brain metastases. Approximately 10%-14% of small cell lung cancer patients exhibit brain metastases at the time of diagnosis, which increases to 50%-80% as the disease progresses. Mean survival with brain metastases is reported to be less than six months, thus calling for improved regimens. Here we present a case series of patients treated with irinotecan for progressive brain metastases in small cell lung cancer, which serves as a reminder of the role of systemic chemotherapy in this setting.

No MeSH data available.


Related in: MedlinePlus

(a, b) Brain metastasis regression after 4 cycles of irinotecan: (a) prechemotherapy and (b) postchemotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4563064&req=5

fig2: (a, b) Brain metastasis regression after 4 cycles of irinotecan: (a) prechemotherapy and (b) postchemotherapy.

Mentions: Five months later, PET/CT showed increased fludeoxyglucose (FDG) activity in a right lower lobe nodule, consistent with residual tumor. There was increased FDG uptake in the right chest wall, left supraclavicular region, retroperitoneum, adrenal glands, bony pelvis, and left lobe thyroid nodule. MRI of the brain showed numerous enhancing foci consistent with metastatic disease (Figure 2(a)). She began second-line chemotherapy with irinotecan: 100 mg/m2 on days 1, 8, and 15 of a 21-day cycle.


Systemic Chemotherapy for Progression of Brain Metastases in Extensive-Stage Small Cell Lung Cancer.

Abdel Karim N, Bhatt A, Chiec L, Curry R - Case Rep Oncol Med (2015)

(a, b) Brain metastasis regression after 4 cycles of irinotecan: (a) prechemotherapy and (b) postchemotherapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4563064&req=5

fig2: (a, b) Brain metastasis regression after 4 cycles of irinotecan: (a) prechemotherapy and (b) postchemotherapy.
Mentions: Five months later, PET/CT showed increased fludeoxyglucose (FDG) activity in a right lower lobe nodule, consistent with residual tumor. There was increased FDG uptake in the right chest wall, left supraclavicular region, retroperitoneum, adrenal glands, bony pelvis, and left lobe thyroid nodule. MRI of the brain showed numerous enhancing foci consistent with metastatic disease (Figure 2(a)). She began second-line chemotherapy with irinotecan: 100 mg/m2 on days 1, 8, and 15 of a 21-day cycle.

Bottom Line: Approximately 10%-14% of small cell lung cancer patients exhibit brain metastases at the time of diagnosis, which increases to 50%-80% as the disease progresses.Mean survival with brain metastases is reported to be less than six months, thus calling for improved regimens.Here we present a case series of patients treated with irinotecan for progressive brain metastases in small cell lung cancer, which serves as a reminder of the role of systemic chemotherapy in this setting.

View Article: PubMed Central - PubMed

Affiliation: The Vontz Center for Molecular Studies, Cincinnati, OH 45267, USA.

ABSTRACT
Lung cancer is the most common cause of cancer related mortality in men and women. Approximately 15% of lung cancers are small cell type. Chemotherapy and radiation are the mainstay treatments. Currently, the standard chemotherapy regimen includes platinum/etoposide. For extensive small cell lung cancer, irinotecan and cisplatin have also been used. Patients with relapsed small cell lung cancer have a very poor prognosis, and the morbidity increases with brain metastases. Approximately 10%-14% of small cell lung cancer patients exhibit brain metastases at the time of diagnosis, which increases to 50%-80% as the disease progresses. Mean survival with brain metastases is reported to be less than six months, thus calling for improved regimens. Here we present a case series of patients treated with irinotecan for progressive brain metastases in small cell lung cancer, which serves as a reminder of the role of systemic chemotherapy in this setting.

No MeSH data available.


Related in: MedlinePlus